Virginia Araiza
Pediatric Endocrinology · Houston, TXNPI 1164757712
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,925 of the $151,272 with a category attached, or 73.3%. AstraZeneca accounts for 96.4% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $55,910 and has fallen 72.4% since, to $15,432 in 2025. Among pediatric endocrinology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 565 payments — averaging $267.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$146K
- AbbVie$1K
- Novo Nordisk$729
- Abbott$510
- Tandem Diabetes Care, Inc.$336
- Insulet Corporation$326
- plus $2K from 24 others
What the payments were for
- Consulting fees$2,5002%
- Speaking & faculty fees$110,92573%
- Travel & lodging$27,74018%
- Food & beverage$10,1007%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 316 | $145,901 |
| AbbVie | 73 | $1,403 |
| Novo Nordisk | 42 | $729 |
| Abbott | 13 | $510 |
| Tandem Diabetes Care, Inc. | 12 | $336 |
| Insulet Corporation | 17 | $326 |
| Dexcom, Inc. | 15 | $276 |
| Sanofi-aventis U.S. LLC | 11 | $236 |
| Xeris Pharmaceuticals, Inc. | 11 | $234 |
| Ascendis Pharma Endocrinology Inc | 7 | $162 |
| Tris Pharma Inc | 1 | $124 |
| Cequr Corporation | 1 | $112 |
| Amphastar Pharmaceuticals, Inc. | 5 | $103 |
| IBSA Pharma Inc. | 6 | $95 |
| Neurocrine Biosciences, Inc. | 3 | $85 |
| Zealand Pharma US, Inc. | 4 | $85 |
| Companion Medical, Inc. | 3 | $77 |
| Eton Pharmaceuticals, Inc. | 2 | $73 |
| Pfizer | 4 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $54 |
| Azurity Pharmaceuticals, Inc. | 2 | $49 |
| Ferring Pharmaceuticals Inc. | 3 | $48 |
| Endo USA, Inc. | 2 | $43 |
| BETA Bionics, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $26 |
| Tolmar, Inc. | 1 | $25 |
| Soleno Therapeutics, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Strensiq$27,194
- Lupron Depot$328
- FreeStyle Libre$238
- Dyanavel XR$124
- CeQur Simplicity$112
- Sogroya$109
- t:slim X2 Insulin Pump with Control-IQ$108
How this compares
$151,272 in reported general payments places this provider in the 95th percentile of 120 pediatric endocrinology providers in Texas.
Other pediatric endocrinology in Houston
- Daniel DesalvoHouston$133K
- Steven WaguespackHouston$37K
- Morey HaymondHouston$30K
- Maria RedondoHouston$19K
- Stephanie SisleyHouston$10K
- Walid KaplanHouston$4K
- Michael YafiHouston$3K
- Luisa RodriguezHouston$2K
- Avni ShahHouston$2K
- Luz CastellanosHouston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.